Tag: Johnson & Johnson

Mixed quarterly results and narrower guidance did not satisfy investors.

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported first-quarter adjusted EPS of $2.71, up 12.4% year-on-year, beating estimates of $2.64. The drug giant reported sales of $21.38 billion, a year-over-year increase of 2.31 TP3T, almost in line with the consensus of $21.39 billion. Operating growth was 3.91 TP3T, compared to adjusted operating growth of 4.01 TP3T. JNJ reported a net profit of $5.35 billion, compared to a net loss of ($491) million in the same period last year, which included a $6.9 billion litigation charge. Innovation

These dividends are very safe.

The new bull market is attracting investors of all trading styles.